About Us Science & Technology Portfolio Join Us Investors & News

Investors & News

Investors

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

News

07.18.2023

The Medicine Maker — Laser Focus: Sitting Down With…Theresa Heah, CEO, Intergalactic Therapeutics, Cambridge, Massachusetts

06.28.2023

Outsourcing-Pharma — Women in Science: Dr. Theresa Heah and her mission to ‘open new frontiers’ in medicine

06.27.2023

Ophthalmology Times — Intergalactic Therapeutics announces positive results for Its non-viral gene therapy platform in ABCA4 retinopathies in non-human primates

06.27.2023

Intergalactic Therapeutics Announces Positive Results for Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies in Non-Human Primates

06.14.2023

Nature Biotechnology — Why gene therapies must go virus-free

05.16.2023

Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023

05.11.2023

Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting

04.29.2023

Ophthalmology Times — ARVO LIVE: Non-viral gene therapy targeting ABCA4 retinopathies

04.20.2023

Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit

04.05.2023

PharmaVoice – Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

03.17.2023

CGTLive – ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Studies

03.16.2023

BioPharma-Reporter – Intergalactic plans to progress non-viral gene therapy program into the clinic

03.15.2023

Ophthalmology Times – Intergalactic Therapeutics announces positive preclinical results of its platform in ABCA4 retinopathies

03.15.2023

Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies

03.08.2023

Labiotech.eu – 5 female-led biotech startups making waves

01.06.2023

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer

01.04.2023

BioSpace – Top Life Sciences Startups to Watch in 2023

01.20.2022

Intergalactic Therapeutics Announces Scientific Advisory Board Membership

10.07.2021

ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding